Zydus and Lupin Partner to Co-Market Semaglutide Injections in India

Zydus Lifesciences and Lupin have entered a licensing and supply agreement to co-market semaglutide injections in India, aiming to expand access to treatments for type 2 diabetes and weight management. Lupin will have semi-exclusive rights to market the drug under brand names Semanext and Livarise, while Zydus will use brands including Semaglyn and Mashema. The collaboration follows the upcoming expiry of Novo Nordisk's semaglutide patent and includes upfront fees and milestone payments to Zydus.